KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Current Deferred Revenue (2016 - 2018)

Gsk has reported Current Deferred Revenue over the past 3 years, most recently at $277.9 million for Q4 2018.

  • For Q4 2018, Current Deferred Revenue fell 12.77% year-over-year to $277.9 million; the TTM value through Dec 2018 reached $277.9 million, down 12.77%, while the annual FY2018 figure was $288.5 million, 9.46% down from the prior year.
  • Current Deferred Revenue for Q4 2018 was $277.9 million at Gsk, down from $318.6 million in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $318.6 million in Q4 2017 and troughed at $196.4 million in Q4 2016.
  • A 3-year average of $264.3 million and a median of $277.9 million in 2018 define the central range for Current Deferred Revenue.
  • Biggest five-year swings in Current Deferred Revenue: skyrocketed 62.22% in 2017 and later decreased 12.77% in 2018.
  • Year by year, Current Deferred Revenue stood at $196.4 million in 2016, then soared by 62.22% to $318.6 million in 2017, then fell by 12.77% to $277.9 million in 2018.
  • Business Quant data shows Current Deferred Revenue for GSK at $277.9 million in Q4 2018, $318.6 million in Q4 2017, and $196.4 million in Q4 2016.